Positions 26–50 of 62.
unpopular opinion: most of what gets said here about MASH is guesswork. It is the sort of thing everyone half-believes and nobody writes down. Asked here what the…
Short version of the title, which is already short: 24th independent test on QSC — 98.4% on a claimed 98.0%, and the trend is the interesting part. Longer version…
dual agonist is the most under-discussed thing on this board. I have gone back and forth on this for months. Phase 2 in a biopsy-confirmed population is a demanding…
dual agonist — 21 things I got wrong before I got it right, and I am aware this is a minority view on this board. What this compound is actually being developed for,…
Vendor-level purity averages over time, built from independent results rather than vendor claims. Transparent methodology, open dataset.
Browse resultsSlightly embarrassed to be asking this, but: someone explain biopsy to me like I have not read a paper in years. Bought small because the evidence base is early. That…
hepatic fat: the version I wish someone had shown me in week 1. Full detail below, and I have tried to keep the editorialising out of it. Bought small because the…
Check-in as promised in the title: small win: hepatic fat stopped being a problem at week 91. Nothing containing this compound is approved anywhere. Research-use-only…
Something I keep coming back to: my ALT moved and I cannot work out whether dual agonist is why. Imaging-derived liver fat fraction is a surrogate. It correlates with…
MASH is doing more work than we give it credit for. Change my mind, genuinely — I have no stake in being right about this. Spent an evening on the histology scoring…
28 weeks on 10mg, full numbers, ask me anything boring. This is a description of what happened to me and not a plan for anybody else. Numbers, in the order they matter:…
genuine question about MASH that I am slightly embarrassed to ask. I would rather ask a basic question now than get this wrong quietly for two months. Asked here what…
Asking properly rather than in a comment on somebody else’s thread: how do you actually verify biopsy. Went slowly because everything published describes a deliberate…
Something I keep coming back to: the biopsy question that gets asked weekly, answered properly. Sent a vial to Janoshik because there was nothing on file. 99.4% against…
Thinking out loud about this: three years of MASH threads, summarised so you do not have to read them. Spent an evening on the histology scoring system and understood…
small win: MASH stopped being a problem at week 43. Full detail below, and I have tried to keep the editorialising out of it. Imaging-derived liver fat fraction is a…
Reference standards, analytical reagents and system-suitability material. If you are running your own method, start with a known.
Reference standards4 months in and hepatic fat is still the thing I get wrong, logged the same way every week so the comparison is at least internally fair. The numbers the title…
Slightly embarrassed to be asking this, but: genuine question about dual agonist that I am slightly embarrassed to ask. Imaging-derived liver fat fraction is a…
Check-in as promised in the title: is it normal to get muscle cramps at week 88. Nothing containing this compound is approved anywhere. Research-use-only material is…
Posting this as a discussion rather than a claim: hepatic fat — 19 things I got wrong before I got it right. Went slowly because everything published describes a…
Homopeptide survo — Medutest came back 98.4% against a claimed 98.0%. One vial, one service, one member paying, which is the only kind of result this board should treat…
4 months in and MASH is still the thing I get wrong. Numbers below. Ask me the boring questions, they are the useful ones. Numbers, in the order they matter: 4 months.…
what changed for me between month 5 and month 8. I am not trying to be the "source?" guy. I would just like a source. Assumed the weight numbers were the point and was…
WWB survo — Medutest came back 99.2% against a claimed 98.5%. One vial, one service, one member paying, which is the only kind of result this board should treat as…
Trying to get a straight answer on this: why does nobody talk about survodutide. Went slowly because everything published describes a deliberate escalation. That is the…
reading MASH threads from 2024 and half of it aged badly. It is the sort of thing everyone half-believes and nobody writes down. Histological endpoints in this field…
Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.
Independent testing plus vendor-level trend data. Community-funded, unaffiliated.
peptidemeter.comSeveral compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.
Reference